Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16Gynecologic 9Thoracic 7Breast 6Genitourinary 4Dermatologic 4Head & Neck 2Other solid neoplasm 1Lymphoid 1Endocrine 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Mesothelioma, Malignant 4Pleural Effusion, Malignant 2Uterine Cervical Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 6pembrolizumab 5fludarabine 4fludarabine phosphate 2amatuximab 2SS1(dsFv)PE38 2tocilizumab 1sotorasib 1sargramostim 1enzalutamide 1entinostat 1defactinib 1bemcentinib 1aldesleukin 1alanosine 1Tablets 1Sorafenib 1Sirolimus 1Quality of Life 1Polymerase Chain Reaction 1Pentostatin 1Pemetrexed 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1Ipilimumab 1Interleukin-12 Subunit p35 1Interferon-gamma 1Interferon-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × aldesleukin × Other solid neoplasm × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡